IN8bio (INAB) Earnings Date & Reports

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

INAB is expected to report earnings to fall 9.38% to -7 cents per share on May 08

Q1'25

Est.

$-0.07

Q4'24

Missed

by $0.01

Q3'24

Beat

by $0.02

Q2'24

Missed

by $0.02

Q1'24

Missed

by $0.03

The last earnings report on March 13 showed earnings per share of -7 cents, missing the estimate of -7 cents. With 771.00K shares outstanding, the current market capitalization sits at 13.86M.

View a ticker or compare two or three

Compare

INAB